Baseline mutation landscape in patients with EGFR 20ins.
NSCLC, Tumor, CR/PR/SD
TUMOR, NSCLC
Tumor mutation landscape defined by cfDNA in advanced NSCLC patients with EGFR 20ins at baseline (To identify potential biomarkers for clinical benefits, baseline genomic profiles from patients with durable clinical benefits (DCB, defined as patients with CR/PR/SD for at least 6 months) were compared to those without. Concurrent TP53 alteration was found enriched in patients without DCB (